ST. LOUIS, Aug. 16 /PRNewswire-FirstCall/ --GenoMed , a Next Generation Disease Management company whose business is public health(TM), today announced that a Texas policeman with paralysis from the waist down due to West Nile virus has accelerated his recovery since starting GenoMed’s treatment last week.
The patient contracted West Nile virus encephalitis a month ago. On Monday of that week he was fine, but by Friday, his legs were so weak that he could only get around by crawling. Although he was hospitalized for the next two weeks, he showed little improvement and had become discouraged.
Last week, on Thursday afternoon, August 10th, the patient and his physician began GenoMed’s protocol. Two days later, on Saturday, August 12th, the patient walked with assistance for 100 steps, compared to only 18 steps on Friday, the day before. Yesterday, Tuesday, August 15th, the patient could easily move the toes in his right foot for the first time, as well as begin to move his right foot sideways.
Said GenoMed’s CEO and Chief Medical Officer, David Moskowitz MD, FACP, “This patient’s accelerated recovery from West Nile virus reinforces the idea that our treatment should be used early in all patients suspected of West Nile virus encephalitis. It is possible that he might not have progressed to paralysis if his physician had started him on our treatment during the very first week of symptoms.” Added Dr. Moskowitz, “Getting the word out about our treatment may literally make the difference between life and death, or in this case a quick recovery versus prolonged paralysis.”
About GenoMed
Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 87% treatment success rate (20 of 23 patients). The first 8 patients were published two years ago in a peer-reviewed medical journal, and GenoMed still has the only published treatment for West Nile virus encephalitis in the medical literature. This summer GenoMed extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed’s website, http://www.genomed.com , by clicking on the “West Nile trial” link. An email address is required for clinical follow-up.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company’s) treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Genomed
CONTACT: David W. Moskowitz MD, CEO of GenoMed, +1-314-983-9933 ordwmoskowitz@genomed.com
Web site: http://www.genomed.com/
